Um estudo avaliando a eficácia e a segurança do Mitapivat em participantes com talassemia alfa ou beta dependente de transfusão (α- ou β-TDT) (ENERGIZE-T)
Um estudo de fase 3, duplo-cego, randomizado, controlado por placebo, multicêntrico avaliando a eficácia e a segurança do mitapivat em indivíduos com talassemia alfa ou beta dependente de transfusão (ENERGIZE-T)
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
The mitapivat group included 171 participants. The placebo group included 87 participants.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 13353
- Charité - UB - CVK - Medizinische Klinik
-
Essen, Alemanha, 45122
- Universitätsklinikum Essen
-
Leipzig, Alemanha, 04103
- Universitätsklinikum Leipzig
-
-
-
-
-
Riyadh, Arábia Saudita, 14611
- King Abdullah International Medical Research Center
-
Riyadh, Arábia Saudita, 90210
- King Khalid University Hospital
-
-
-
-
-
Ribeirão Preto, Brasil, 14051-260
- Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São Paulo, Brasil, 04006-002
- GSH Banco de Sangue de São Paulo
-
-
-
-
-
Kyustendil, Bulgária, 2500
- MHAT "Dr. Nikola Vasiliev" AD
-
Pleven, Bulgária, 5800
- UMHAT "Dr. Georgi Stranski" Pleven
-
Plovdiv, Bulgária, 4002
- UMHAT "Sveti Georgi" EAD
-
Sofia, Bulgária, 1756
- SHATHD Sofia
-
Stara Zagora, Bulgária, 6000
- UMHAT "Prof. Dr. Stoyan Kirkovich"
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 2T9
- Foothills Medical Centre
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2C4
- Toronto General Hospital, University Health Network
-
-
-
-
-
Hovedstaden, Dinamarca, 2100
- Rigshospitalet
-
-
-
-
-
Abu Dhabi, Emirados Árabes Unidos
- Burjeel Medical City
-
-
-
-
-
Barcelona, Espanha, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, Espanha, 28046
- Hospital Universitario La Paz
-
Murcia, Espanha, 30120
- Hospital Universitario Virgen Arrixaca
-
Seville, Espanha, 41013
- Hospital Universitario Virgen del Rocío
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85016-7710
- Phoenix Children's Hospital
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- San Diego Hospital, UC San Diego Health
-
Oakland, California, Estados Unidos, 94609-1809
- Children's Hospital Oakland
-
Palo Alto, California, Estados Unidos, 94304-1601
- Stanford Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Boston Children's Hospital
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201-2196
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, Estados Unidos, 10065-4870
- Weill Cornell Medical Center
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710-3038
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Penn Medicine - University of Pennsylvania Health System
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Seattle Cancer Care Alliance, University of Washington
-
-
-
-
-
Créteil, França, 94010
- CHU Hôpital Henri Mondor
-
Lyon, França, 69003
- Hôpital Edouard Herriot, CHU de Lyon
-
Marseille, França, 13385
- CHU Hôpital de la Timone
-
Paris, França, 75015
- Hôpital Necker Enfants Malades
-
-
-
-
-
Achaia, Grécia, 26504
- University General Hospital of Patras
-
Athens, Grécia, 11527
- Children's Hospital Agia Sophia, National and Kapodistrian University of Athens Medical School
-
Athens, Grécia, 115 26
- Laiko General Hospital
-
Ioannina, Grécia, 455 00
- University Hospital of Ioannina
-
Thessaloniki, Grécia, 546 42
- Ippokrateio General Hospital
-
-
-
-
-
Amsterdam, Holanda, 1105 AZ
- Amsterdam Universitair Medisch Centrum, Locatie AMC
-
Utrecht, Holanda, 3584 CX
- Universitair Medisch Centrum Utrecht
-
Westzeedijk 353, Holanda, 3015 AA
- Erasmus MC
-
-
-
-
-
Brindisi, Itália, 72100
- Ospedale "A. Perrino" - Brindisi
-
Cagliari, Itália, 09121
- Ospedale Pediatrico Microcitemico
-
Ferrara, Itália, 44124
- Ospedale Sant'Anna
-
Genova, Itália, 16128
- Ente Ospedaliero Ospedali Galliera
-
Milan, Itália, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Modena, Itália, 41124
- A.O.U Di Modena
-
Naples, Itália, 80138
- AOU L. Vanvitelli Universita degli Studi della Campania Luigi Vanvitelli
-
Orbassano, Itália, 10043
- A.O.U. San Luigi Gonzaga
-
-
-
-
-
Beirut, Líbano, 9999
- Chronic Care Center
-
-
-
-
-
Alor Star, Malásia, 05460
- Hospital Sultanah Bahiyah
-
Johor Bahru, Malásia, 80100
- Hospital Sultanah Aminah Johor Bahru
-
Kota Kinabalu, Malásia, 88586
- Hospital Queen Elizabeth, Kota Kinabalu
-
Kuala Lumpur, Malásia, 50300
- Hospital Tunku Azizah
-
Kuantan, Malásia, 25100
- Hospital Tengku Ampuan Afzan
-
Kuching, Malásia, 93586
- Hospital Umum Sarawak
-
Pandan Indah, Malásia, 68000
- Hospital Ampang
-
Pulau Pinang, Malásia, 10990
- Hospital Pulau Pinang
-
-
-
-
-
London, Reino Unido, WC1E 6BT
- University College London
-
London, Reino Unido, W12 0HS
- Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
-
-
-
-
Bangkok, Tailândia, 10400
- Phramongkutklao Hospital
-
Bangkok, Tailândia, 10400
- Ramathibodi Hospital
-
Bangkok, Tailândia, 10700
- Faculty of Medicine Siriraj Hospital
-
Chiang Mai, Tailândia, 50200
- Maharaj Nakorn Chiang Mai Hospital
-
Khon Kaen, Tailândia, 40000
- Srinagarind Hospital, Khon Kaen University
-
Mueang Phitsanulok, Tailândia, 65000
- Naresuan University Hospital
-
Pathum Wan, Tailândia
- King Chulalongkorn Memorial Hospital
-
-
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
-
-
-
Adana, Turquia (Türkiye), 1130
- Acibadem Adana Hospital
-
Antalya, Turquia (Türkiye), 07059
- Akdeniz University Faculty of Medicine
-
Balcalı, Turquia (Türkiye), 01330
- Çukurova University
-
Bornova, Turquia (Türkiye), 35040
- Ege University Faculty of Medicine
-
Fatih, Turquia (Türkiye), 34093
- Istanbul University Faculty of Medicine
-
Mersin, Turquia (Türkiye)
- Hacettepe University
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Greater than or equal to (≥)18 years of age at the time of providing informed consent;
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on deoxyribonucleic acid (DNA) analysis;
- Considered transfusion-dependent, defined as 6 to 20 red blood cells (RBC) units transfused and ≤6-week transfusion-free period during the 24-week period before randomization;
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization;
- Women of childbearing potential (WOCBP) must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle or agree to use two forms of contraception, one of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method;
- Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.
Exclusion Criteria:
-
Pregnant, breastfeeding, or parturient;
-
Documented history of homozygous or heterozygous sickle hemoglobin (Hb S) or hemoglobin C (Hb C);
-
Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
-
Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization;
-
Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization;
-
History of malignancy (active or treated) ≤5 years before providing informed consent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;
-
History of active and/or uncontrolled cardiac or pulmonary disease ≤6 months before providing informed consent;
-
Hepatobiliary disorders;
-
Estimated glomerular filtration rate <45 milliliters per minute (mL/min)/1.73 meter (m)^2 by Chronic Kidney Disease Epidemiology Collaboration creatinine equation;
-
Nonfasting triglycerides >440 milligrams per deciliter (mg/dL) (5 millimoles per liter [mmol/L]);
-
Active infection requiring systemic antimicrobial therapy at the time of providing informed consent;
-
Positive test for hepatitis C virus antibody (HCVAb) with evidence of active HCV infection, or positive test for hepatitis B surface antigen (HBsAg);
-
Positive test for human immunodeficiency virus (HIV)-1 antibody (Ab) or HIV-2 Ab;
-
History of major surgery (including splenectomy) ≤6 months before providing informed consent and/or a major surgical procedure planned during the study;
-
Current enrollment or past participation (≤12 weeks before administration of the first dose of study drug or a timeframe equivalent to 5 half-lives of the investigational study drug, whichever is longer) in any other clinical study involving an investigational treatment or device;
-
Receiving strong CYP3A4/5 inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer); or strong CYP3A4 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization;
-
Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed. The testosterone dose and preparation must be stable for ≥12 weeks before randomization;
-
Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate, Opadry® II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and Federal Food, Drug, and Cosmetic (FD&C) Blue #2]);
-
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Mitapivat
Participants randomized to receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 48 weeks in the double-blind (DB) period and for up to 5 years in the open label extension (OLE) period. |
Tablets
Outros nomes:
|
|
Comparador de Placebo: Placebo
Participants randomized to receive placebo matching mitapivat, orally, BID for 48 weeks in the DB period followed by mitapivat 100 mg, orally, BID for up to 5 years in the OLE period. |
Tablets
Outros nomes:
Tablets |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)
Prazo: Double-blind Period: Baseline through Week 48
|
TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders. |
Double-blind Period: Baseline through Week 48
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Período duplo-cego: concentrações plasmáticas de mitapivat
Prazo: Período duplo-cego: pré-dose na semana 12; pré-dose na semana 24; pré-dose, 0,5, 1, 3, 5, 7 horas após a dose na semana 36
|
Período duplo-cego: pré-dose na semana 12; pré-dose na semana 24; pré-dose, 0,5, 1, 3, 5, 7 horas após a dose na semana 36
|
|
|
Período duplo-cego: Concentração plasmática máxima observada (CMAX) de Mitapivat
Prazo: Período duplo-cego: pré-dose, 0,5, 1, 3, 5, 7 horas após a semana 36
|
Período duplo-cego: pré-dose, 0,5, 1, 3, 5, 7 horas após a semana 36
|
|
|
Período duplo-cego: tempo para atingir a concentração plasmática máxima observada (TMAX) de Mitapivat
Prazo: Período duplo-cego: pré-dose, 0,5, 1, 3, 5, 7 horas após a semana 36
|
Período duplo-cego: pré-dose, 0,5, 1, 3, 5, 7 horas após a semana 36
|
|
|
Período duplo-cego: Tempo da última concentração quantificável (Tlast) de Mitapivat
Prazo: Período duplo-cego: pré-dose, 0,5, 1, 3, 5, 7 horas após a semana 36
|
Período duplo-cego: pré-dose, 0,5, 1, 3, 5, 7 horas após a semana 36
|
|
|
Período duplo-cego: Concentração sanguínea do trifosfato de adenosina (ATP)
Prazo: Período duplo-cego: pré-dose no dia 1; pré-dose na semana 12; pré-dose na semana 24; pré-dose, 0,5, 1, 3, 5, 7 horas após a dose na semana 36
|
Período duplo-cego: pré-dose no dia 1; pré-dose na semana 12; pré-dose na semana 24; pré-dose, 0,5, 1, 3, 5, 7 horas após a dose na semana 36
|
|
|
Período duplo-cego: Concentração sanguínea de 2,3-difosfogliclicerato (2,3-dpg)
Prazo: Período duplo-cego: pré-dose no dia 1; pré-dose na semana 12; pré-dose na semana 24; pré-dose, 0,5, 1, 3, 5, 7 horas após a dose na semana 36
|
Período duplo-cego: pré-dose no dia 1; pré-dose na semana 12; pré-dose na semana 24; pré-dose, 0,5, 1, 3, 5, 7 horas após a dose na semana 36
|
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR2
Prazo: Double-blind period: Baseline through Week 48
|
TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders. |
Double-blind period: Baseline through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR3
Prazo: Double-blind period: Baseline up to Week 13 through Week 48
|
TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders. |
Double-blind period: Baseline up to Week 13 through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR4
Prazo: Double-blind period: Baseline up to Week 13 through Week 48
|
TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders. |
Double-blind period: Baseline up to Week 13 through Week 48
|
|
Double-blind Period: Percent Change From Baseline in Transfused RBC Units
Prazo: Double-blind Period: Baseline, Week 13 through Week 48
|
Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed. |
Double-blind Period: Baseline, Week 13 through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence
Prazo: Double-blind Period: Baseline through Week 48
|
Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Iron Levels
Prazo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on Iron levels. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Serum Ferritin Levels
Prazo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on serum ferritin levels. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Total Iron Binding Capacity
Prazo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on total iron binding capacity. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels
Prazo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
Prazo: Double-blind Period: From first dose of study drug up to week 48
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious & non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE. |
Double-blind Period: From first dose of study drug up to week 48
|
|
Open-label Extension Period: Number of Participants With TEAEs, Serious TEAEs, Related TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to 3
Prazo: Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious & non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE. |
Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
|
|
Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
Prazo: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
|
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule. |
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
|
|
Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
Prazo: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
|
Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses. |
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Cadeira de estudo: Medical Affairs, Agios Pharmaceuticals, Inc.
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- AG348-C-018
- 2021-000212-34 (Número EudraCT)
- 2024-512747-23-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .